CompanyQiagen N.V.
Netherlands
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).
Private/Public:
public
Phone:+31 77 320 8400
Fax:+31 77 320 8409
Email:[email protected]
Website:http://www.qiagen.com/
Address:Hulsterweg 82, 5912 PL Venlo, Netherlands
1984
Since
1
Country
7
Top Service Categories
157
Sub-Service Categories
Top Services
Molecule Types
For Services/Products
Business Sectors
For Services/Products
Product Groups
For Services/Products
Therapeutic Categories
Main Disease Areas
Bioanalytical
Bioanalytical assays
Microbiology
Specific Services - microbiology
Diagnostics
Diagnostic services/equipment
- Diagnostic assay development/manufacturing
- Diagnostic kit/reagent manufacturing
- General diagnostics assay/kit services
- Diagnostic analytical performance services
- Diagnostic assay verification and validation
- Diagnostic final kit box-packaging
- Diagnostic formulation development
- Diagnostic reagent development
- Diagnostic/OEM manufacturing
- Kits for fully automated testing
- Kits for manual/semi automated testing
- Specific diagnostic kit/reagents
- Diagnostic equipment manufacturing
- Diagnostic laboratory developed testing (LTDs)
- Diagnostic software services
- Diagnostic technologies/capabilities
- Diagnostic test purpose
Research Supplies
Life Sciences Supplies/Reagents
Discovery and Preclinical
| Facility Type | Address | Telephone | City | Fax | Country | State Code | Service Categories | Facility Size | Year Built | Number Of Employees | Note |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D/Innovation Centers,Manufacturing Facilities,Regional/Country Headquarters,Distribution | 6 & 7F, R3-B, High-Tech Industrial Park, Nanshan District, Shenzhen 518057 | Shenzhen | China | ||||||||
| R&D/Innovation Centers,Manufacturing Facilities,Regional/Country Headquarters | 19300 Germantown Road, Germantown MD 20874 | 800-426-8157 | Germantown | 800-718-2056 | United States of America | MD-Maryland | 1045440 square foot | ||||
| R&D/Innovation Centers,Regional/Country Headquarters | Skelton House, Lloyd Street North, Manchester M15 6SH | 1800 555 049/0808 234 3665 | Manchester | 1800 555 048/0808 234 3918 | United Kingdom | ||||||
| R&D/Innovation Centers,Regional/Country Headquarters | Garstligweg 8, CH-8634 Hombrechtikon | +41 55 254 21 11 | Hombrechtikon | +41 55 254 21 00 | Switzerland | ||||||
| R&D/Innovation Centers,Regional/Country Headquarters | Bodenseeallee 20, 78333 Stockach | +49-7771-91660 | Stockach | +49-7771-9166218 | Germany | ||||||
| Regional/Country Headquarters | QIAGEN Straße 1 D-40724 Hilden | 02103-29-12000 | Hilden | 02103-29-22000 | Germany | 786000 square foot | |||||
| Regional/Country Headquarters | PO Box 169, 169 Chadstone Centre VIC 3148 | 1-800-243-800/066 | Chadstone | 03-9840-9888 | Australia | ||||||
| Regional/Country Headquarters | Quellinstraat 49, 2018 Antwerp | 0800 79612 | Antwerp | 0800 79611 | Belgium | ||||||
| Regional/Country Headquarters | Avenida do Café, 277 – 2º andar Cj.202, Vila Guarani (Zona Sul), São Paulo/SP – 04113-001 | 55-11-5079-4000 | São Paulo | Brazil | |||||||
| Regional/Country Headquarters | 181 Bay Street, Suite 4400, Toronto, Ontario M5J 2T3 | 800-572-9613 | Toronto | 800-713-5951 | Canada | ||||||
| Regional/Country Headquarters | Block 20, Landscape Park, 88 Da Er Wen Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203 | 021-3865 3865 | Shanghai | 021-3865 3965 | China | ||||||
| Regional/Country Headquarters | Fruebjergvej 3, boks 79, 2100 København Ø | 80-885945 | Copenhagen | 80-885944 | Denmark | ||||||
| Regional/Country Headquarters | PL 3810, 00002 Helsinki | 0800-914416 | Helsinki | 0800-914415 | Finland | ||||||
| Regional/Country Headquarters | 3 avenue du Canada, LP 809, 91974 Courtaboeuf Cedex | 01-60-920-926 | Courtaboeuf Cedex | 01-60-920-925 | France | ||||||
| Regional/Country Headquarters | Corporate One, Plot No. 5, District Center, Jasola, New Delhi – 110025 | +91 11 47128301 | New Delhi | +91 11 4712 8302 | India | ||||||
| Regional/Country Headquarters | Via Filippo Sassetti 16, 20124 Milano | +39 800 789 544 | Milano | +39 800 789 660 | Italy | ||||||
| Regional/Country Headquarters | Forefront Tower II, 3-13-1 Kachidoki, Chuo-ku, Tokyo 104-0054 | 03-6890-7300 | Tokyo | 03-5547-0818 | Japan | ||||||
| Regional/Country Headquarters | Seoul Square 5th Floor, Hangang-Daero 416, Jung-Gu, Seoul 100-714 | 080-000-7145/7146 | Seoul | 1544 7146 | South Korea | ||||||
| Regional/Country Headquarters | Level 9, Tower 8, Avenue 5, Horizon Phase 2, Bangsar South, No. 8 Jalan Kerinchi, 59200 Kuala Lumpur | +603-2718-6000 | Kuala Lumpur | +603-2241-2010 | Malaysia | ||||||
| Regional/Country Headquarters | Insurgentes Sur 2453 – 801, Colonia Tizapán San Ángel, C.P. 01090 México, D.F. | 01-800-7742639 | San Ángel | 01-800-1122330 | Mexico | ||||||
| Regional/Country Headquarters | Postboks 137 Sentrum, NO-0102 Oslo | 800-18859 | Oslo | 800-18817 | Sweden | ||||||
| Regional/Country Headquarters | ul. Powstańców Śląskich 95, 53-332 Wrocław | +48 71 71 07 893 | Wrocław | +48 71 71 07 801 | Poland | 48600 square foot | |||||
| Regional/Country Headquarters | 8 Commonwealth Lane #02-02, Singapore 149555 | +65 6854 8100 | Commonwealth | +65 6854 8184 | Singapore | ||||||
| Regional/Country Headquarters | Torshamnsgatan 35, 16440 Kista | 020-790282 | Kista | 020-790582 | Sweden | ||||||
| Regional/Country Headquarters | Block C, Cedar Tree Office Park, Corner Cedar Road and Broadacres, Stinkwood Close, Johannesburg 2044 | +27 11 244 8540 | Johannesburg | +27 86 653 6034 | South Africa | ||||||
| Regional/Country Headquarters | Baldiri Reixac, 4 – 8, 08028 Barcelona | +34 91 630 7050 | Barcelona | +34 91 630 5145 | Spain | ||||||
| Regional/Country Headquarters | 689 Bhiraj Tower 41th Floor Unit No. 4105-4107, Sukhumvit Road, North Klongton Sub-District, Vadtana District, Bangkok 10110 | +66-2117-7500/7501/7511 | Bangkok | +66-2117-7501 | Thailand | ||||||
| Global Corporate Headquarters | Hulsterweg 82, 5912 PL Venlo | 8002 2076/0800 0229592 | Venlo | 8002 2073/0800 0229593 | Netherlands |
- (03.Mar.2021) QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics
- (02.Mar.2021) QIAGEN Launches QIAcube Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
- (24.Feb.2021) INOVIO and QIAGEN Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO's VGX-3100 for Advanced Cervical Dysplasia
- (18.Feb.2021) QIAGEN Announces Digital Partner Program with Five Initial Partnerships
- (09.Feb.2021) QIAGEN Beats Outlook for Fourth Quarter and Full-Year 2020, Reaffirms Expectations for Further Growth in 2021
- (20.Jan.2021) QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus
- (20.Jan.2021) QIAGEN Plans to Resubmit EUA Submission in the U.S. For QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021
- (19.Jan.2021) QIAGEN Adopts GNS Healthcare's Gemini - The in Silico Patient Across Multiple Cancers
- (13.Jan.2021) Personal Genome Diagnostics and QIAGEN Collaborate to Offer Integrated Genomic Testing and Interpretation Support
- (07.Jan.2021) QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute
- (17.Dec.2020) QIAGEN Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-Linked Credit Facility
- (11.Dec.2020) QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds and Price to Non-US Holders to Sell Outstanding Convertible Notes Due 2021
- (10.Dec.2020) QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds and Results of Offer to Non-US Holders to Sell the Outstanding Convertible Notes Due 2021
- (10.Dec.2020) QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds and Solicits Offers from Non-US Holders to Sell Any and All of the Outstanding Convertible Notes Due 2021
- (08.Dec.2020) QIAGEN Increases Outlook for 2020 and 2021
- (07.Dec.2020) QIAGEN to Launch QuantiFERON SARS-CoV-2 for Research Into Causes, Spread and Control of COVID-19 Through T-Cell Response
- (18.Nov.2020) QIAGEN Collaborates With BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck
- (16.Nov.2020) QIAGEN Launches NeuMoDx Multiplex Test to Complete Range of SARS-CoV-2 Testing Solutions in Europe and Other Markets
- (11.Nov.2020) QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test That Can Accurately Analyze Over 30 Samples Per Hour
- (11.Nov.2020) QIAGEN Announces Start of Share Repurchase for up to $100 Million
- (10.Nov.2020) TScan Therapeutics Announces Partnership With QIAGEN to Develop T Cell-Based Laboratory Test for Comprehensive COVID-19 Immune Response
- (28.Oct.2020) QIAGEN Launches QIAseq Human Exome TR Insights, a New Integrated Solution for Whole Exome Sequencing
- (27.Oct.2020) Ad Hoc Announcement According to Art. 17 Market Abuse Regulation
- (27.Oct.2020) QIAGEN Reports Strong Results for Third Quarter and First Nine Months of 2020 and Increases Outlook for Full-Year 2020
- (13.Oct.2020) QIAGEN Reports Strong Preliminary Results for Third Quarter of 2020
- (05.Oct.2020) QIAGEN to Complement COVID-19 Testing Portfolio With Novel Kit That Simplifies and Accelerates PCR Analysis for Research Applications
- (17.Sep.2020) Bio-Techne and QIAGEN Announce Expansion and Extension of Exosome Partnership
- (17.Sep.2020) QIAGEN Fully Acquires NeuMoDx Molecular, Inc., Rounding out Portfolio of PCR-Based Diagnostic Automation Systems
- (08.Sep.2020) QIAGEN to Launch Rapid Portable Test That Can Analyze Over 30 Samples Per Hour for SARS-CoV-2 Antigen
- (24.Aug.2020) QIAGEN to Launch Easy-To-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization
- (18.Aug.2020) QIAGEN Expands Integrated Coronavirus NGS and Software Solutions to Accelerate COVID-19 Research
- (13.Aug.2020) QIAGEN to Continue Successful Growth Strategy Focused on Execution and Greater Value Creation After Voluntary Public Takeover Offer Falls Short
- (13.Aug.2020) Press Release From Davidson Kempner Regarding Qiagen
- (13.Aug.2020) Thermo Fisher Scientific Announces Results of Offer to Acquire QIAGEN, Lapse of Offer and Termination of Acquisition Agreement
- (11.Aug.2020) Thermo Fisher Scientific Provides Process Overview for the Announcement of Final Offer Results
- (10.Aug.2020) HTG Molecular Diagnostics Announces New Commercialization and Distribution Agreement for Companion Diagnostics With QIAGEN
- (04.Aug.2020) Thermo Fisher Scientific Confirms Offer to Acquire QIAGEN Shares Expires on August 10
- (04.Aug.2020) QIAGEN Reports Full Results for Second Quarter and First Half of 2020
- (03.Aug.2020) Davidson Kempner[1] Now Holds an 8.0% Stake and Finds Qiagen's Standalone Prospects Highly Attractive
- (22.Jul.2020) QIAGEN Announces Publication of Supplemental Reasoned Position Statement for Proposed Acquisition by Thermo Fisher
- (16.Jul.2020) Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement
- (15.Jul.2020) Davidson Kempner Letter to Qiagen NV
- (13.Jul.2020) QIAGEN Provides Update on Q2 2020 Results, Announces Strong Outlook for Q3 and FY 2020, and 2021 Perspectives in Light of Coronavirus Pandemic
- (09.Jul.2020) QIAGEN Announces Preliminary Results for Q2 2020
- (30.Jun.2020) QIAGEN Shareholders Approve All Agenda Items Related to Acquisition by Thermo Fisher Scientific at Annual General Meeting
- (23.Jun.2020) QIAGEN Provides Information on Potential Capital Gain from Its Minority Investment in ArcherDX
- (22.Jun.2020) QIAGEN Announces Plans to Release Preliminary Q2 2020 Results
- (28.May.2020) QIAGEN Builds on Leading Position in Precision Medicine With Novel Solutions in Oncology
- (18.May.2020) QIAGEN Announces Publication of Reasoned Position Statement for Proposed Acquisition by Thermo Fisher and Date for Annual General Meeting
- (18.May.2020) Thermo Fisher Scientific Publishes Offer Document for Voluntary Tender Offer for All Ordinary Shares of QIAGEN N.V
- (06.May.2020) QIAGEN Reports Full Results for First Quarter of 2020
- (05.May.2020) QIAGEN Expects Higher Results for Q2 2020 Based on Trends to Date and Suspends Outlook for Full-Year 2020
- (27.Apr.2020) Gilson and QIAGEN Announce Collaboration Aiming to Make Manual Nucleic Acid Extraction More Efficient and Reproducible
- (24.Apr.2020) BGI Expands EUA Label for SARS-CoV-2 RT-PCR Test With MGI Automated Extraction Methods and Additional PCR Systems
- (15.Apr.2020) QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI (Encorafenib) Based Regimen in Metastatic Colorectal Cancer
- (09.Apr.2020) QIAGEN Announces Preliminary Q1 2020 Results
- (07.Apr.2020) SensID Product Development in Collaboration with Qiagen
- (31.Mar.2020) QIAGEN Receives U.S. FDA EUA for QIAstat-Dx Test Kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus
- (31.Mar.2020) Fully Mobilized to Support Global Response to COVID-19 Pandemic
- (24.Mar.2020) QIAGEN Names Thierry Bernard as Chief Executive Officer
- (24.Mar.2020) QIAGEN Releases QIAstat-Dx Test Kit to the U.S. as First Syndromic Test for Detection of SARS-CoV-2 Coronavirus Under New FDA Policy
- (18.Mar.2020) QIAGEN Launches QIAstat-Dx Test Kit for Detection of SARS-CoV-2 Coronavirus in Germany Following Derogation by BfArM
- (17.Mar.2020) QIAGEN Dramatically Ramping Up Global Production Capacity for RNA Extraction Kits for Use in Detection of SARS-CoV-2 Coronavirus
- (16.Mar.2020) NuProbe Announces Strategic Collaboration With QIAGEN, Completes Multiple CE IVD Product Registrations
- (13.Mar.2020) QIAGEN Gains BARDA Funding for Approval Process of QIAstat-Dx Test Kit for SARS-CoV-2 Coronavirus
- (12.Mar.2020) Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests